A phase 3 trial confirms “the potent anti-leukemic effect” of consolidation with allogeneic transplant in older patients with acute myeloid leukemia, according to researchers.

Acute myeloid leukaemia (AML) is mainly characterized by an increase in the number of myeloid cells in the bone marrow and a decrease in mature cells, accounting for 28% of leukaemia cases, with a ...

Kura Oncology's stock plummeted 50% after announcing a collaboration with Kyowa Kirin, making it a less attractive ...

The study demonstrated a poor prognosis overall for patients with acute myeloid leukemia (AML) who were previously treated ...

Ambit said recently it expects to have 110 clinical sites recruiting AML patients into its trial ... Celgene's Vidaza (azacitidine) or low dose cytarabine. For Daiichi Sankyo, the acquisition ...

The ODAC considered whether the new low dose in combination with daunorubicin and cytarabine had an acceptable ... benefit profile of Mylotarg in AML.” Mace Rothenberg, chief development officer ...

Exicure, Inc. , today announced that on January 19, 2025, Exicure Inc. ("the Company") entered into a Share Purchase Agreement with GPCR Therapeutics Inc., a Korean corporation ("GPCR"), pursuant to ...

The cancer changes the growth and development of leukocytes (white blood cells), and the stem cells from which they develop. The deadliest type of blood cancer is generally considered to be acute ...

Jan. 14, 2025 — A team of researchers has developed a new biomaterial with high potential in in the treatment of bone lesions or minimal residual disease in multiple myeloma patients. The ...

Objective Bone marrow-derived myeloid cells accumulate in the liver as monocytes and macrophages during the progression of obesity-related non-alcoholic fatty liver disease (NAFLD) to steatohepatitis ...

Acute kidney injury (AKI) is a common, heterogeneous, multifactorial condition, which is part of the overarching syndrome of acute kidney diseases and disorders. This condition’s incidence highest in ...